Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With Cancer.

Autor: Hanna PE; Division of Nephrology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Anumolu RK; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Motwani SS; Lahey Hospital and Medical Center, Burlington, Massachusetts, USA., Chen KL; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA., Katz-Agranov N; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Green-Lingren O; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Yilmam OA; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Jhaveri KD; Northwell Health, New Hyde Park, New York, USA.; Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA., Kitchlu A; Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada., Kala J; Division of Renal Diseases and Hypertension, Department of Internal Medicine, University of Texas Health Science Center at Houston-McGovern Medical School, Texas, USA., Sise ME; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Gupta S; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Publikováno v: Kidney international reports [Kidney Int Rep] 2024 Mar 13; Vol. 9 (6), pp. 1897-1902. Date of Electronic Publication: 2024 Mar 13 (Print Publication: 2024).

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer.

Autor: Hanna PE; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Strohbehn IA; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Moreno D; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Harden D; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Seethapathy R; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Sawtell R; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Wang Q; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Ouyang T; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Katz-Agranov N; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Dinulos J; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA., Wander SA; Massachusetts General Hospital, Department of Medicine, Division of Hematology and Oncology, Boston, MA, USA., Gupta S; Brigham and Women's Hospital Department of Medicine, Division of Renal Medicine, Boston, MA, USA.; Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, MA, USA., Sise ME; Massachusetts General Hospital, Department of Medicine, Division of Nephrology, Boston, MA, USA. msise@mgb.org.

Publikováno v: NPJ breast cancer [NPJ Breast Cancer] 2023 Aug 19; Vol. 9 (1), pp. 70. Date of Electronic Publication: 2023 Aug 19.

Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors.

Autor: Gupta S; Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Medical Oncology, Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, MA, USA., Hanna PE; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA., Ouyang T; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA., Yamada KS; Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Sawtell R; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA., Wang Q; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA., Katz-Agranov N; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA., Feghali L; Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Krasner CN; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bouberhan S; Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA., Castro CM; Department of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA., Sise ME; Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.

Publikováno v: Journal of the National Cancer Institute [J Natl Cancer Inst] 2023 Jul 06; Vol. 115 (7), pp. 831-837.

Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Autor: Vergara-Cadavid J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Johnson PC; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Kim HT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard School of Public Health, Boston, Massachusetts., Yi A; Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts., Sise ME; Division of Nephrology, Massachusetts General Hospital, Massachusetts., Leaf DE; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Hanna PE; Division of Nephrology, Massachusetts General Hospital, Massachusetts., Ho VT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Cutler CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Antin JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gooptu M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kelkar AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wells SL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Nikiforow S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Koreth J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Romee R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Soiffer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Shapiro RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Gupta S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: sgupta21@bwh.harvard.edu.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2023 Jul; Vol. 29 (7), pp. 455.e1-455.e9. Date of Electronic Publication: 2023 Apr 02.

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer.

Autor: Gupta S; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Strohbehn IA; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Wang Q; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Hanna PE; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Seethapathy R; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Prosek JM; Division of Nephrology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio, USA., Herrmann SM; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA., Abudayyeh A; Division of Internal Medicine, Section of Nephrology, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Malik AB; Division of Nephrology, University of Washington, Seattle, Washington, USA., Loew S; Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany., Carlos CA; Department of Medicine, Division of Nephrology, University of California San Francisco, San Francisco, California, USA., Chang WT; Department of Clinical Medicine, Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, Division of Cardiology, Chi-Mei Medical Center, Tainan, Taiwan; Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan., Beckerman P; Institute of Nephrology and Hypertension, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel., Mithani Z; Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, Florida, USA., Shah CV; Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplant, University of Florida, Gainesville, Florida, USA., Renaghan AD; Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia, USA., de Seigneux S; Service of Nephrology, Department of Medicine, University Hospital of Geneva, Geneva, Switzerland., Campedel L; Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Hôpital Pitié-Salpêtrière, Institut universitaire de cancérologie, CLIP Galilée, Groupe de Recherche Interdisciplinaire Francophone en Onco-néphrologie (GRIFON), Paris, France., Kitchlu A; Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada., Shin DS; Department of Medicine, Division of Hematology-Oncology, Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California, USA., Coppock G; Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Lumlertgul N; Department of Critical Care, Guy's & St Thomas Hospital, London, UK; Division of Nephrology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Garcia P; Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA., Ortiz-Melo DI; Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA., Rashidi A; Division of Nephrology and Hypertension, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA., Sprangers B; Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology (Rega Institute for Medical Research), KU Leuven, Leuven, Belgium; Division of Nephrology, University Hospitals Leuven, Leuven, Belgium., Aggarwal V; Department of Nephrology and Hypertension, Northwestern University and Feinberg School of Medicine, Chicago, Illinois, USA., Benesova K; Department of Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Jhaveri KD; Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Great Neck, New York, USA., Cortazar FB; New York Nephrology Vasculitis and Glomerular Center, Albany, New York, USA., Weins A; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Zuo Y; Department of Pathology and Laboratory Medicine, University of Miami, Miami, Florida, USA., Mooradian MJ; Division of Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA., Reynolds KL; Division of Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA., Leaf DE; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Sise ME; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: msise@partners.org.

Publikováno v: Kidney international [Kidney Int] 2022 Oct; Vol. 102 (4), pp. 930-935. Date of Electronic Publication: 2022 Aug 11.